Background Carboplatin-based combinations are established in platinum-sensitive recurrent ovarian cancer. To improve the therapeutic index, new platinum-based combinations are required. Pemetrexed is a multi-targeted antifolate inhibiting thymidylate synthase. The aim of this study was to determine the maximally tolerated dose (MTD) and dose-limiting toxicity (DLT) and to characterize toxicities of the combination of pemetrexed (Pem) and carboplatin (Cb). Design A standard three-patient cohort dose escalation was performed starting at Cb AUC-5 and Pem 500 mg/m 2 . Patients with platinum-sensitive recurrent ovarian cancer were eligible. Two levels of Cb (AUC-5, 6) and five levels of Pem (500, 600, 700, 800, and 900 mg/m 2 ) were evaluated. DLTs were based on cycle 1.
carboplatin and paclitaxel regimen over platinum monotherapy in platinum-sensitive patients [5] . Today, most of the patients will receive first-line chemotherapy with paclitaxel and a platinum compound, so that the cumulative neurotoxicity of platinum and paclitaxel compromises the retreatment with these agents [6, 7] . Furthermore, many patients prefer to avoid alopecia in this palliative therapeutic setting. Therefore, various study groups are currently exploring other non-taxane-containing platinum combinations in order to optimize the therapeutic index for patients with platinum-sensitive recurrent ovarian cancer [7, 8] .
Pemetrexed is a multi-targeted antifolate inhibitor of thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT) [9] and is given in combination with vitamin supplementation. It is currently approved for the treatment of malignant pleural mesothelioma and non-small cell lung cancer in conjunction with cisplatin [10, 11] and for the second-line monotherapy of non-small cell lung cancer [12] .
Various preclinical studies indicate significant activity of pemetrexed against ovarian xenograft tumors and ovarian carcinoma cells [13] [14] [15] . The toxicity profile of pemetrexed is generally favorable without severe hematologic or non-hematologic side effects including a very low rate of neurotoxicity and alopecia [10, 11] . Therefore, pemetrexed is a good candidate for novel platinum-based combination chemotherapy in recurrent ovarian cancer.
Based on these results, a phase-I study was initiated to further evaluate the toxicity profile and dose-limiting toxicity of the combination of pemetrexed plus carboplatin in patients with platinum-sensitive recurrent ovarian cancer.
Patients and methods

Design
Patients were enrolled at two German centers (Charité: 18 patients, Jena 2 patients). The trial was performed in accordance with the principles of Good Clinical Practice (GCP) and the Declaration of Helsinki. Protocol approval was gained from the institutional review board or the local ethics committee of each participating institution. An independent monitoring institute was responsible for data control.
A prospective, separate phase-I and II was planned to investigate the safety and efficacy of this new chemotherapy combination. As in the study protocol, primary defined individual clinical study reports from the phase-I and phase-II were planned. Here, we present the data from the dose finding study.
The primary objective of the phase-I study was to determine the maximum tolerated dose (MTD) of the combination therapy of pemetrexed and carboplatin when administered to patients with platinum-sensitive recurrent ovarian cancer.
The secondary objectives of this study were:
• to determine the dose-limiting toxicities (DLT) of the combination therapy of pemetrexed and carboplatin, • to determine the quantitative and qualitative toxicities of pemetrexed in combination with carboplatin, • to determine a recommended dose of the combination therapy of pemetrexed and carboplatin for future phase-II studies, and • to document the antitumor activity of pemetrexed and carboplatin in patients with platinum-sensitive recurrent ovarian cancer through tumor response assessment.
Patients
Women C 18 years of age were eligible who had platinum-sensitive recurrent cancer of the ovary, fallopian tube, or peritoneum, at least 6 months after completion of primary standard therapy with surgery and first-line combination therapy with platinum and paclitaxel. Patients were required to have measurable lesions or non-measurable disease as defined by Response Criteria in Solid Tumors (RECIST) [16] or had to be evaluable for CA-125 response evaluation according to the GCIG-criteria [17] . Eastern Cooperative Oncology Group (ECOG) performance status had to be B2, patients were required to have normal hematologic, liver, and renal function with laboratory parameters within the normal range, including a glomerular filtration rate C 45 ml/min based on the standard Cockcroft and Gault formula or on measured GFR using an appropriate radiolabeled method (51-CrEDTA or Tc99 m-DTPA), serum creatinine levels B1.5 mg/dl, and an adequate bone marrow function (absolute neutrophil count [ANC] C 1.5 9 10 9 /l and platelets C100 9 10 9 /l). Patients suffering from a secondary malignancy or serious concomitant systemic disorders or psychiatric disease were excluded from the study, as were subjects receiving other cytotoxic, immunological, hormonal, or targeted therapy. All patients provided written informed consent. Patients were excluded if they had more than two previous lines of therapy for ovarian cancer or a serious concomitant systemic disorder that would compromise the ability to complete the study.
Treatment plan
Intravenous premedication consisting of a 5-HT3-antagonist was administered 15 min prior to chemotherapy infusion. Grade 3 or 4 nausea and/or vomiting should be managed with appropriate changes in an anti-emetic regimen and in regard to the discretion of the investigator.
Patients received pemetrexed IV over a 5-10 min bolus, followed by carboplatin IV (calculated via Cockcroft-Gault Equation) over 30-60 min, given every 21 days for 6 cycles (up to 8 cycles could be administered at the investigators discretion if clinical benefit was expected).
Both study drugs were dissolved in 250 ml of 0.9% saline. Patients were required to receive oral folic acid 350-1,000 lg daily at least 1-2 weeks before cycle 1 until 3 weeks after the last pemetrexed dose and 1,000 lg vitamin B 12 intramuscularly every 9 weeks, starting at least 1-2 weeks before cycle 1, and then every 9 weeks until 3 weeks after the last pemetrexed dose [18] . To prevent skin rash, dexamethasone 4 mg orally (or equivalent) was given twice daily for 3 days, starting on day 1 prior to pemetrexed administration.
Seven dose levels were defined upfront (Table 1) . Patient accrual and dose escalation depended upon the observed pattern of DLTs. According to the protocol, a cohort of 3-6 patients for each dose level had to be enrolled.
If none of the three initial patients of a given level experienced a DLT in cycle 1, enrollment proceeded to the next dose level. If one of the initial 3 patients of a given level experienced a DLT in cycle 1, additional patients had to be enrolled up to a maximum of six patients at that level. If no more than one patient experienced a DLT in cycle 1, patient enrollment proceeded to the next level. If two of the three initial patients of a given level experienced a DLT in cycle 1, that level had to be considered the maximum tolerated dose (MTD). Dose escalation to the next level was not allowed until the last patient of a given dose level (that is, either the third or sixth patient) had completed the entire first cycle.
A 5-HT3-antagonist was given intravenously 15 min prior to every chemotherapy cycle. Use of erythropoietin stimulating agents was allowed; however, no primary prophylactic use of granulocyte colony-stimulating factor (G-CSF) was allowed.
Toxicity
Toxicity was assessed after each cycle, graded according to the NCI-Common Terminology Criteria for Adverse Events (CTCAE) v3.0, August 9, 2006 [19] . The following toxicities, if observed during cycle 1 of treatment, were considered a dose-limiting toxicity (DLT):
• CTCAE Grade 4 neutropenia (ANC \ 0.5 9 10 9 /l) lasting C7 days, • febrile neutropenia (ANC \ 1.0 9 10 9 /l, fever 38.5°C, no clinically or microbiologically documented infection), • CTCAE Grade 4 thrombocytopenia (platelets \ 25.0 9 10 9 /l), • any grade hemorrhage with CTCAE Grade C3 thrombocytopenia (50.0 9 10 9 /l), • CTCAE Grade C3 non-hematologic toxicity (excluding nausea, vomiting, or CTCAE Grade 3 ALT or AST that returned to baseline prior to next treatment), • treatment delay of more than 1 week due to unresolved Grade 3 or 4 toxicity.
Blood count and blood chemistry were carried out regularly once a week. Subsequent chemotherapy cycles were allowed if the absolute neutrophil count was [1.5 9 10 9 /l and platelet count was C100 9 10 9 /l. Treatment could be postponed up to 1 week in case of toxicity. Reduction to dose level -1 was required for treatment delays exceeding 1 week. Protocol treatment was discontinued if the patient required cycle delay longer than 1 week due to unresolved grade 3 or greater toxicity.
Response
Patients were assessed before treatment, during treatment and every 3 months after treatment for 2 years, then every 6 months for 3 years. Physical examination, CA-125 (according to the criteria established by Vergote et al. [17] ), and radiological evaluation of measurable tumor lesions were performed as baseline assessment. Evaluation of response was performed every other cycle (within 7 days) using the same method that was employed at baseline and in any case of suspected progression of disease. Clinical response was determined by physical examination and ultrasound, computer tomography (CT), or magnetic resonance imaging (MRI) scans. Response was measured according to RECIST criteria [16] .
Statistical analysis
There were 20 patients enrolled in this phase-I study. This number depended on the dose levels studied in determining the primary endpoint of this study. The primary endpoint, determination of the MTD was not achieved. All secondary Table 2 .
Treatment profile
The treatment profile is summarized in Table 4 .
Dose reduction
There were three dose reductions (two at dose level 3 and one at dose level 4) necessary in the 115 cycles of pemetrexed. For carboplatin, there were three dose reductions in 112 cycles (two at dose level 3 and one at dose level 4). In one patient, additional intrapatient dose reduction was necessary.
Treatment discontinuation
No patient required treatment discontinuation due to unacceptable toxicity. Prior to protocol completion, seven patients discontinued treatment (five due to progressive disease, and two due to patient choice).
Dose-limiting toxicity
We observed only one DLT: in dose level 3, one patient experienced grade 4 neutropenia for 7 days without clinical squeal. No other dose-limiting toxicities were observed. There were no treatment-related deaths in this phase-I study.
Two serious adverse events were observed, but none of them was considered to be related to study treatment: One patient suffered from gastrointestinal bleeding (at dose level 1). This 60-year-old patient had a diffuse peritoneal carcinomatosis and diffuse liver metastasis. At the time of the gastrointestinal bleeding, the blood parameters were within the normal range with thrombocytes of 109 9 10 3 lL and Hb of 10.5 g/dl. The bleeding was managed conservatively. The second patient suffered from subileus (at dose level 6). This event was managed conservatively and was considered to be related to the underlying diffuse peritoneal carcinomatosis and not due to the study drug itself. Five patients required dose reduction due to toxicity.
Hematological toxicity
No neutropenic fever, sepsis, or chemotherapy-related deaths occurred during the trial. Overall, hematological side effects were manageable and without sequelae. Grade 4 neutropenia occurred in one patient in dose level 3. No other grade 4 hematologic toxicities were observed; details are listed in Table 5 .
A prophylactic treatment with Erythropoietin was permitted, but in no patient, erythropoietin was administered.
Non-hematological toxicity
Non-hematological side effects were mild and rarely greater than grade 2. Three patients suffered from grade 3 toxicity: one patient with nausea (dose level 3), one patient with dyspnea (dose level 4) and one patient with allergic reaction to carboplatin (dose level 1). No grade 4 non-hematological side effects occurred. Patients did not experience neurotoxicity higher than grade 2. Seven patients suffered from grade 1 and one patient from grade 2 neurotoxicity, both were attributed to the previous chemotherapy with carboplatin and paclitaxel. Grade 1 alopecia was observed in six patients. Allergic reaction to carboplatin occurred in five patients with grade 1 and in one patient with grade 3. Seventeen patients experienced grade 1 or 2 nausea, 14 experienced grades 1 or 2 vomiting. Grade 1 diarrhea occurred in five patients. No unexpected non-hematological toxicity was observed; details are listed in Table 6 .
Response and survival
Nineteen patients could be assessed for response, of which 17 were analyzed according to the CA-125 response criteria; two patients were analyzed by RECIST criteria. Twelve patients achieved complete remission (63.2%, 95% CI: 41.5-84.9), four patients achieved partial response (21.1%, 95% CI: 2.8-39.4%), one patient had stable disease (5.3%, 95% CI: 0-15.3%), and two patients had progressive disease (10.5%, 95% CI: 0-24.3%). By intent-to-treat, the response rate was estimated to be 80% (95% CI: 62.5-97.5%). The median follow-up was 9.8 months (95% CI 6.2-14 months). At the time of final data analysis, 18 of the 20 enrolled patients had progressive disease, 17 patients were alive.
Discussion
Platinum-based combination therapy with paclitaxel or gemcitabine is currently considered to be the standard second-line treatment for patients with platinum-sensitive relapsed ovarian cancer [5, 7] . The incidence of neurotoxicity in patients receiving conventional paclitaxel and carboplatin as first-line treatment was estimated to be 54% of all patients [6] , while approximately 13% suffer from grade 2 to 3 neurotoxicity. In a large phase-III trial of the ICON-AGO intergroup evaluating treatment with carboplatin and paclitaxel as second-line therapy, a significantly higher incidence of grade 2 to 4 neurotoxicity (20%) was observed in comparison with single agent platinum (1%) [5] . This observation is notable, especially because in this trial, only 43% of the patients had received platinum-and taxane-based combination chemotherapy during first-line therapy. Since at the present time most patients will be treated with carboplatin and paclitaxel as first-line therapy, the incidence of neurotoxicity will probably be significantly higher and consequently might have substantial impact on the quality of life of these patients.
Thus, in a situation where cure is generally not achieved, there is high clinical need for alternative platinum-based combinations to improve the therapeutic index with special attention to patients' quality of life. Pemetrexed seems to be an attractive candidate for a platinum combination. It has proven activity in mesothelioma and non-small cell lung cancer, and neurotoxicity is rare [10] [11] [12] . In the present study, eight patients suffered from neurotoxicity, which preexisted from prior taxane-based first-line chemotherapy and was not attributed to pemetrexed.
To our knowledge, this is the first dose-escalating study of the combination pemetrexed and carboplatin in ovarian cancer. We observed only one DLT: in dose level 3, one patient experienced grade 4 neutropenia for 7 days without clinical squeal. Despite the fact that we applied pemetrexed up to a dose of 900 mg/m 2 and carboplatin up to an AUC of 6, we did not reach the maximum tolerated dose. Matulonis et al. combined pemetrexed at 500 mg/m 2 and carboplatin at AUC 5 in a phase-II study [20] . Grade 3 and 4 hematologic toxicities included neutropenia (41%), thrombocytopenia (23%), and anemia (9%). In their study, the response rate was 51.1% (95% CI: 35.8-66.3%) without any patients achieving a complete response. Despite the methodical limitation of cross-trial comparison, response rate was substantially higher in the current trial (80%) with 12 patients achieving CR. In contrast to our study, the study by Matulonis included more than 50% of patients with more than two prior chemotherapies.
These differences in the inclusion criteria or a potential effect of the different applied dose may explain the different toxicity profiles and response rates of both trials. Another explanation might be the difference in response evaluation, as Matulonis et al. used RECIST criteria in contrast to GCIG CA-125 criteria utilized in the current trial.
Regarding vitamin supplementation, the current trial is, to our knowledge, also the first dose-escalating study of the combination of pemetrexed and carboplatin. Until today, one phase-I study with pemetrexed and carboplatin in 27 patients with malignant pleural mesothelioma has been conducted, but this study was near completion when supplementation with folic acid and vitamin B 12 was instituted; therefore, these patients were not supplemented. The MTD for pemetrexed was 500 mg/m 2 and for carboplatin AUC 6 and was defined by two episodes of grade 4 neutropenia (data on file). Vitamin B 12 supplementation causes a statistically significant reduction in plasma homocysteine concentrations over time and a significant reduction in the frequencies of severe hematologic toxicities and nonhematological toxicities in patients receiving pemetrexed therapy [21] . In contrast to the phase-I study in mesothelioma, in the present study, all patients received vitamins. This might be an explanation for the improved dose tolerance we observed.
Despite the favorable hematological and non-hematological toxicity profile in the present study, the optimal dose of pemetrexed in a combination with carboplatin is not yet defined. Recently, Vergote et al. presented the results of a randomized study comparing pemetrexed 500 mg/m 2 with 900 mg/m 2 in patients with platinumresistant ovarian cancer [22] . There were no differences in response rate or clinical outcome, but the lower dose had a significantly better toxicity profile.
Additionally, there is now growing evidence that doses higher than the currently approved 500 mg/m 2 of pemetrexed do not improve the efficacy in several tumor types including ovarian, breast, and non-small cell lung cancer [23] [24] [25] .
Despite the fact that it is unclear whether or not these results can be translated into the platinum-pemetrexed combination, it is very unlikely that a higher dose of pemetrexed could yield a higher efficacy.
Nevertheless, it can be criticized that in the present study, further dose escalation may be possible because the MTD was not reached. But it should be mentioned that different study groups [7, 26] demonstrated the efficacy of specific carboplatin-based combinations such as pegylated doxorubin/carboplatin or gemcitabine/carboplatin without using the highest possible dosages, and there is no evidence showing a clear effect of the dose on progression-free survival or overall survival in relapsed ovarian cancer.
Therefore, the committee of the present study has decided to use-for the subsequent phase-II trial-a dose of 500 mg/m 2 for pemetrexed in combination with carboplatin according AUC 6.
The primary objective of this study is to define the clinical response rate; secondary objectives are the identification of acute and late toxicities as well as the time up to progression and overall survival. Furthermore, various potential biomarkers will be explored in the phase-II trial. It is only when validated biochemical response markers are available, those patients who will benefit from this new agent can be identified [27] .
